Prolonged course of pure red cell aplasia after erythropoietin therapy.
Pure red cell aplasia (PRCA) caused by neutralising anti-erythropoietin antibodies is a very rare disease. Since 1998, an increased incidence of PRCA in patients with kidney failure following treatment with recombinant human erythropoietin (rhEpo) has been reported, mostly in Europe. In most cases, PRCA was cured by immunosuppressive therapy, immunoglobulins, plasmapheresis or renal transplantation. We report an exceptionally prolonged course of PRCA over 68 months despite renal transplantation and different immunosuppressive regimens.
Renal Division, Department of Medicine, University Hospital, Zurich, Switzerland.
L
L
Nigg
U
U
Schanz
P M
PM
Ambühl
J
J
Fehr
E B
EB
Bachli
D000328:Adult; D000906:Antibodies / Q000276:immunology*; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000276:immunology* / Q000628:therapy; D013997:Time Factors; D017211:Treatment Failure
D000906:Antibodies; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin